Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12315352 | 0.86 | USP2 (0.65) | USP2GAALMNAHTTNPSR1 | |
| SCHEMBL4555722 | 0.84 | USP2 (0.67) | USP2GAALMNAKCNH2HRH3 | |
| SCHEMBL15010487 | 0.82 | USP2 (0.63) | USP2GAAKCNH2HRH3HTT | |
| SCHEMBL27532497 | 0.81 | USP2 (0.67) | USP2GAALMNAKCNH2HRH3 | |
| SCHEMBL12189227 | 0.80 | USP2 (0.71) | USP2GAALMNAHTTNPSR1 | |
| SCHEMBL10312340 | 0.80 | USP2 (0.61) | USP2GAALMNAKCNH2HRH3 | |
| SCHEMBL7861726 | 0.79 | L3MBTL1 (0.63) | USP2GAALMNAKCNH2HRH3 | |
| SCHEMBL14094452 | 0.79 | GAA (0.59) | USP2GAALMNAHTTNPSR1 | |
| SCHEMBL27406555 | 0.79 | USP2 (0.63) | USP2GAALMNAKCNH2HRH3 | |
| SCHEMBL12646347 | 0.78 | USP2 (0.68) | USP2GAALMNAHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585891-B2 | Alpha hydroxy amides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9585891-B2 | Alpha hydroxy amides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | HCAR1, NAA40, HCAR2 | USP2 4101/4885GAA 2288/4885LMNA 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.